Cytox is developing a diagnostic test and therapeutic cures for Alzheimer’s Disease which is estimated to affect 15 million people worldwide. The company is a university spin-out based on groundbreaking academic research into the role of the cell cycle in neuro-degenerative diseases.

Status current

Associated Fund Advantage Growth Fund,
UK Innovation & Science Seed Fund

Sector Medical / Biotechnology


Associated Team Members

Relevant News

Cytox Announces Participation In Insight Alzheimer’s Study

Participation will aid comparison of SNP genotyping with biomarker status Cytox Ltd, an innovative developer…

read more

Cytox Signs Research Agreement with AIBL and Partner Organisations

Collaboration Will Contribute To Further Refinement Of Diagnostic SNPs For Alzheimer’s Disease 1 June 2015:…

read more

Cytox Secures £3.5M in Further Funding

Manchester & Oxford, UK, 25 January 2013 – Cytox Limited, developer of a unique blood…

read more

Cytox awarded new Innovate UK funding for Alzheimer’s disease testing

Important clinical evaluation of pioneering approach for risk assessment 8 March 2018: Oxford &...

read more

More Companies in Medical / Biotechnology

Your browser is out-of-date!

Update your browser to view this website correctly.Update my browser now